Lauren P Wallner1, Jeffrey M Slezak2, Ronald K Loo3, Roshan Bastani4, Steven J Jacobsen5. 1. Assistant Professor of Internal Medicine and Epidemiology at the University of Michigan in Ann Arbor, and an Adjunct Investigator at the Department of Research and Evaluation for Kaiser Permanente Southern California in Pasadena. lwallner@med.umich.edu. 2. Research Manager of Biostatistics for the Department of Research and Evaluation for Kaiser Permanente Southern California in Pasadena. jeff.m.slezak@kp.org. 3. Regional Assistant Medical Director for the Southern California Permanente Medical Group and Chair of the Kaiser Permanente Interregional Urology Chiefs. ronald.k.loo@kp.org. 4. Professor of Health Management and Policy at the University of California, Los Angeles. bastani@ucla.edu. 5. Senior Director of Research in the Department of Research and Evaluation for Kaiser Permanente Southern California in Pasadena. steven.j.jacobsen@kp.org.
Abstract
CONTEXT: Few studies have assessed the longer-term quality of preventive care in prostate cancer (PCa) survivors. OBJECTIVE: To compare the rates of preventive services among PCa survivors five years before and after diagnosis, to men without PCa. DESIGN: Men enrolled in Kaiser Permanente Southern California with newly diagnosed PCa (2002-2008) were matched 1:1 to men without a PCa diagnosis on age, race, and timing of prostate-specific antigen test (N = 31,180). The use of preventive services, including colorectal cancer screening, diabetes tests, lipid panels, and influenza and pneumococcal vaccinations was assessed 5 years before and after diagnosis (or index date for controls). MAIN OUTCOME MEASURES: Relative rates (RRs) of use were calculated for cases and controls separately and compared using Poisson regression, adjusting for comorbidities and outpatient utilization in 2014. RESULTS: Overall, the rates of preventive services were lower among men with PCa vs men without PCa. However, in the 5 years after diagnosis, rates of preventive service use for all services were greater among PCa survivors vs men without PCa (colorectal cancer: RR = 1.05, 95% confidence interval [CI] = 1.01-1.10; lipids: RR = 1.10, 95% CI = 1.08-1.11; hemoglobin A1C: RR = 1.17, 95% CI = 1.14-1.19; glucose: RR = 1.24, 95% CI = 1.23-1.26; influenza vaccine: RR = 1.05, 95% CI = 1.03-1.07; pneumococcal vaccine: RR = 1.03, 95% CI = 0.97-1.09). CONCLUSION: Delivery of preventive care improved after PCa diagnosis, with survivors receiving comparable preventive care to men without PCa during the five years following diagnosis.
CONTEXT: Few studies have assessed the longer-term quality of preventive care in prostate cancer (PCa) survivors. OBJECTIVE: To compare the rates of preventive services among PCa survivors five years before and after diagnosis, to men without PCa. DESIGN:Men enrolled in Kaiser Permanente Southern California with newly diagnosed PCa (2002-2008) were matched 1:1 to men without a PCa diagnosis on age, race, and timing of prostate-specific antigen test (N = 31,180). The use of preventive services, including colorectal cancer screening, diabetes tests, lipid panels, and influenza and pneumococcal vaccinations was assessed 5 years before and after diagnosis (or index date for controls). MAIN OUTCOME MEASURES: Relative rates (RRs) of use were calculated for cases and controls separately and compared using Poisson regression, adjusting for comorbidities and outpatient utilization in 2014. RESULTS: Overall, the rates of preventive services were lower among men with PCa vs men without PCa. However, in the 5 years after diagnosis, rates of preventive service use for all services were greater among PCa survivors vs men without PCa (colorectal cancer: RR = 1.05, 95% confidence interval [CI] = 1.01-1.10; lipids: RR = 1.10, 95% CI = 1.08-1.11; hemoglobin A1C: RR = 1.17, 95% CI = 1.14-1.19; glucose: RR = 1.24, 95% CI = 1.23-1.26; influenza vaccine: RR = 1.05, 95% CI = 1.03-1.07; pneumococcal vaccine: RR = 1.03, 95% CI = 0.97-1.09). CONCLUSION: Delivery of preventive care improved after PCa diagnosis, with survivors receiving comparable preventive care to men without PCa during the five years following diagnosis.
Authors: Claire F Snyder; Kevin D Frick; Melinda E Kantsiper; Kimberly S Peairs; Robert J Herbert; Amanda L Blackford; Antonio C Wolff; Craig C Earle Journal: J Clin Oncol Date: 2009-01-21 Impact factor: 44.544
Authors: K Robin Yabroff; Pamela F Short; Steven Machlin; Emily Dowling; Heather Rozjabek; Chunyu Li; Timothy McNeel; Donatus U Ekwueme; Katherine S Virgo Journal: Am J Prev Med Date: 2013-09 Impact factor: 5.043
Authors: Lisa M Lowenstein; Jennifer Andreozzi Ouellet; William Dale; Lin Fan; Supriya Gupta Mohile Journal: J Geriatr Oncol Date: 2014-12-24 Impact factor: 3.599
Authors: Claire F Snyder; Kevin D Frick; Robert J Herbert; Amanda L Blackford; Bridget A Neville; Antonio C Wolff; Michael A Carducci; Craig C Earle Journal: J Clin Oncol Date: 2013-02-11 Impact factor: 44.544
Authors: Claire F Snyder; Craig C Earle; Robert J Herbert; Bridget A Neville; Amanda L Blackford; Kevin D Frick Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Katelyn K Jetelina; Simon Craddock Lee; Quiera S Booker-Nubie; Udoka C Obinwa; Hong Zhu; Michael E Miller; Navid Sadeghi; Umber Dickerson; Bijal A Balasubramanian Journal: J Cancer Surviv Date: 2022-01-05 Impact factor: 4.062